Antitubercular inhaled therapy: Opportunities, progress and challenges

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 4, 2005, Pages 430-435

  Pandey, Rajesh ^a   Khuller, G K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Drug delivery; Liposomes; Nebulization; Polymers; Tuberculosis

Indexed keywords

ALGINIC ACID; AMINOSALICYLIC ACID; AMYLOPECTIN; ANTIBIOTIC AGENT; ANTIMYCOBACTERIAL AGENT; CHITOSAN; DIPALMITOYLPHOSPHATIDYLCHOLINE; DNA; DRUG CARRIER; ETHIONAMIDE; GAMMA INTERFERON; GENTAMICIN; ISONIAZID; KANAMYCIN; LECTIN; LIPOSOME; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLYGLACTIN; POLYMER; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG STABILITY; DRUG TARGETING; DRY POWDER; ENCAPSULATION; FEASIBILITY STUDY; HEALTH CARE COST; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NEBULIZATION; NONHUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; POWDER INHALER; REVIEW; RISK REDUCTION; SIDE EFFECT; SUSTAINED DRUG RELEASE;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; CAPSULES; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; TUBERCULOSIS, PULMONARY;

EID: 17444377960     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki027     Document Type: Review

References (47)

1. Dessanges, J. F. (2001). A history of nebulization. Journal of Aerosol Medicine 14, 65-71.
2. Smith, C. V., Sharma, V. & Sacchettini, J. C. (2004). TB drug discovery: addressing issues of persistence and resistance. Tuberculosis (Edinburgh, Scotland) 84, 45-55.
3. Kilinc, O., Ucan, E. S., Cakan, M. D. A. et al. (2002). Risk of tuberculosis among health care workers: can tuberculosis be considered as an occupational disease? Respiratory Medicine 96 506-10.
4. O'Riorden, T. G. (2002). Formulations and nebulizer performance. Respiratory Care 47, 1305-12.
5. Le Brun, P. P., de Boer, A. H., Heijerman, H. G. et al. (2000). A review of the technical aspects of drug nebulization. Pharmacy World and Science 22, 75-81.
6. O'Callaghan, C. & Barry, P. W. (1997). The science of nebulized drug delivery. Thorax 52, Suppl. 2, S31-S44.
7. Rau, J. L. (2002). Design principles of liquid nebulization devices currently in use. Respiratory Care 47, 1257-75.
8. Kuhn, R. J. (2001). Formulation of aerosolised therapeutics. Chest 120, Suppl., 94S-8S.
9. Dailey, L. A., Schmehl, T., Gessler, T. et al. (2003). Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. Journal of Controlled Release 86, 131-44.
10. Lipworth, B. J. (2000). Targets for inhaled treatment. Respiratory Medicine 94, Suppl. D, S13-S16.
11. Telzak, E., Fazal, B. A., Pollard, C. L. et al. (1997). Factors influencing time to sputum conversion among patients with smear positive pulmonary tuberculosis. Clinical and Infectious Diseases 25, 666-70.
12. Sacks, L. V., Pendle, S., Orlovic, D. et al. (2001). Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear positive pulmonary tuberculosis. Clinical and Infectious Diseases 32, 44-9.
13. Condos, R., Rom, W. N. & Schluger, N. W. (1997). Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 349, 1513-5.
14. Koh, W. J., Kwon, O. J., Suh, G. Y. et al. (2004). Six months therapy with aerosolised interferon gamma for refractory multidrug-resistant pulmonary tuberculosis. Journal of Korean Medical Science 19, 167-71.
15. Ahsan, F., Rivas, I. P., Khan, M. A. et al. (2002). Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. Journal of Controlled Release 79, 29-40.
16. Basu, M. K. & Lala, S. (2004). Macrophage specific drug delivery in experimental leishmaniasis. Current Molecular Medicine 4, 681-9.
17. Khuller, G. K., Kapur, M. & Sharma, S. (2004). Liposome technology for drug delivery against mycobacterial infections. Current Pharmaceutical Design 10, 3263-74.
18. Pandey, R., Sharma, S. & Khuller, G. K. (2004). Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs. Indian Journal of Experimental Biology 42, 562-6.
19. Gilbert, B. E. (1996). Liposome aerosols in the management of pulmonary infections. Journal of Aerosol Medicine 9, 111-22.
20. Pandey, R., Sharma, S. & Khuller, G. K. (2004). Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. International Journal of Antimicrobial Agents 24, 93-4.
21. Justo, O. R. & Moraes, A. M. (2003). Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Delivery 10, 201-7.
22. Kurunov, I. N., Ursov, I. G., Krasnov, V. A. et al. (1995). Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis. Problemy Tuberkuleza 1, 38-40.
23. Pandey, R., Sharma, S. & Khuller, G. K. (2004). Liposome-based antitubercular drug therapy in a guinea model of tuberculosis. International Journal of Antimicrobial Agents 23 414-5.
24. Vyas, S. P., Kannan, M. E., Jain, S. et al. (2004). Design of liposomal aerosol for improved delivery of rifampicin to alveolar macrophages. International Journal of Pharmaceutics 269 37-49.
25. Thomas, D. A., Myers, M. A., Wichert, B. et al. (1991). Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 99, 1268-70.
26. Pandey, R. & Khuller, G. K. (2004). Polymer based drug delivery systems for mycobacterial infections. Current Drug Delivery 1, 195-201.
27. Jain, R. A. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-90.
28. O'Hara, P. & Hickey, A. J. (2000). Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterisation. Pharmaceutical Research 17, 955-61.
29. Suarez, S., O'Hara, P., Kazantseva, M. et al. (2001). Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharmaceutical Research 18, 1315-9.
30. Suarez, S., O'Hara, P., Kazantseva, M. et al. (2001). Airways delivery of rifampicin microparticles for the treatment of tuberculosis. Journal of Antimicrobial Chemotherapy 48, 431-4.
31. Sethuraman, V. V. & Hickey, A. J. (2002). Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech 3, E28.
32. Sharma, R., Saxena, D., Dwivedi, A. K. et al. (2001). Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharmaceutical Research 18, 1405-10.
33. Mukherjee, J. S., Rich, M. L., Socci, A. R. et al. (2004). Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363, 474-81.
34. Tsapis, N., Bennett, D., O'Driscoll, K. et al. (2003). Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinburgh, Scotland) 83, 379-85.
35. Rao, G. C., Kumar, M. S., Mathivanan, N. et al. (2004). Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 59, 5-9.
36. Jacobs, C. & Muller, R. H. (2002). Production and characterisation of a budesonide nanosuspension for pulmonary administration. Pharmaceutical Research 19, 189-94.
37. Bala, I., Hariharan, S. & Kumar, M. N. V. R. (2004). PLGA nanoparticles in drug delivery: the state of the art. Critical Reviews in Therapeutic Drug Carrier Systems 21, 387-422.
38. Lamprecht, A., Ubrich, N., Hombreiro, P. et al. (1999). Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. International Journal of Pharmaceutics 184, 97-105.
39. Pandey, R., Sharma, A., Zahoor, A. et al. (2003). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. Journal of Antimicrobial Chemotherapy 52, 981-6.
40. Abu-Dahab, R., Schafer, U. F. & Lehr, C. M. (2001). Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. European Journal of Pharmaceutical Sciences 14, 37-46.
41. Sharma, A., Sharma, S. & Khuller, G. K. (2004). Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolised antitubercular drug carriers for treatment of tuberculosis. Journal of Antimicrobial Chemotherapy 54, 761-6.
42. Dingler, A. & Gohla, S. (2002). Production of solid lipid nanoparticles (SLN): scaling up feasibilities. Journal of Microencapsulation 19, 11-6.
43. Grayson, A. C., Voskerician, G., Lynn, A. et al. (2004). Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. Journal of Biomaterials Science, Polymer Edition 15, 1281-304.
44. Videira, M. A., Botelho, M. F., Santos, A. C. et al. (2002). Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. Journal of Drug Targeting 10, 607-13.
45. Pandey, R. & Khuller, G. K. (2005). Solid lipid nanoparticle based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinburgh, Scotland), in press.
46. Bivas-Benita, M., van Meijgaarden, K. E., Franken, K. L. et al (2004). Pulmonary delivery of chitosan-DNA nanoparticles; enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22, 1609-15.
47. Rikimaru, T. (2004). Endobronchial tuberculosis. Expert Review of Anti-Intective Therapy 2, 245-51.